RecruitingNCT06035250

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Deep Learning-Based Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Sponsor

Chinese Academy of Sciences

Enrollment

200 participants

Start Date

Sep 10, 2023

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer Image Pathology

Summary

This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using artificial intelligence (AI) to analyze CT scans and biopsy images to predict how well stomach cancer will respond to chemotherapy given before surgery (neoadjuvant chemotherapy), to help guide more personalized treatment decisions. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced stomach (gastric) cancer confirmed by pathology - You received standard neoadjuvant chemotherapy and have documentation of your treatment - You had CT and biopsy imaging taken within one month of starting chemotherapy - You have complete preoperative records and post-surgery response grading **You may NOT be eligible if...** - Your CT or biopsy images are too unclear for analysis - You have another active cancer diagnosis at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeoadjuvant Chemotherapy

Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.

Locations(22)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

Peking Union Medical College Hospital

Beijing, China

Peking University Cancer Hospital & Institute

Beijing, China

Peking University People's Hospital

Beijing, China

Xiangya Hospital of Central South University

Changsha, China

Fujian Cancer Hospital

Fuzhou, China

Fujian Medical University Union Hospital

Fuzhou, China

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Guangzhou, China

First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, China

Nanfang Hospital of Southern Medical University

Guangzhou, China

Sixth Affiliated Hospital, Sun Yat-sen University

Guangzhou, China

Yunnan Cancer Hospital

Kunming, China

Cancer Hospital of Guangxi Medical University

Nanning, China

The Affiliated Hospital of Qingdao University

Qingdao, China

Ruijin Hospital

Shanghai, China

First Hospital of China Medical University

Shenyang, China

The First Affiliated Hospital of Soochow University

Suzhou, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, China

Henan Cancer Hospital

Zhengzhou, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China

Zhenjiang First People's Hospital

Zhenjiang, China

San Raffaele University Hospital, Italy

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06035250

Related Trials

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT0548921196 locations

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT0692192818 locations

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT045579691 location

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT0576893217 locations

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

NCT054834912 locations